top of page

Empowering Personalized Medicine through Innovative Diagnostic Solutions

Our Story

Founded in 2015, Stratificare™ is at the forefront of pioneering diagnostic solutions that drive personalized medicine and optimize clinical outcomes.

We excel in integrating protein diagnostics with artificial intelligence, enabling precision healthcare.

With innovation and partnership at our core, we are building a global predictive protein biomarker and data platform company.

We continuously seek cutting-edge protein biomarker technologies and collaborate with hospitals, specialty clinics, and clinical laboratories to deliver impactful solutions to patients, their families, and society.

Our Mission

To revolutionize healthcare by empowering personalized medicine through innovative diagnostic solutions, ensuring optimal clinical outcomes and transforming lives globally.

Our Vision


Lead the development of cutting-edge protein diagnostic technologies combined with artificial intelligence to provide precise and actionable healthcare insights.


Forge strong partnerships with hospitals, specialty clinics, and clinical laboratories to expand the reach and impact of our diagnostic solutions.tion you would like to feature.


Enable healthcare providers and patients to make informed decisions through early and accurate diagnosis, optimizing treatment pathways and improving quality of life.


Strive to enhance patient care, support their families, and contribute positively to society by advancing the field of personalized medicine.

By continually pushing the boundaries of diagnostic innovation and fostering strategic collaborations, Stratificare™ is committed to transforming healthcare and improving patient outcomes worldwide.




Anrhony Chua
Chief Executive Officer

  • Linkedin

Anthony obtained his PhD in Virology from the National University of Singapore (NUS), and is an alumnus of the NUS Overseas College. He was trained in high-tech entrepreneurship at the University of Pennsylvania and later, at INSEAD. Since 2006, he has been involved with numerous BioTech/MedTech startups and tech transfer offices both locally and internationally. Anthony’s work contributed to the acquisition of Protez Pharmaceuticals by Novartis, and together with Professor Mary Ng, played instrumental roles in attracting Fujitsu Laboratories Limited to establish their very first BioTech research facility in Singapore


Mary Mah
Chief Scientific Officer

  • Linkedin

Professor Ng is an internationally renowned scientist with more than 30 years of in-depth experience in Virology research. Being among the first to study the replication cycle of the SARS virus, she is the scientist behind the acclaimed SARS virus scanning electron micrograph showcased by the Smithsonian National Museum of Natural History, CDC, National Geographic and CNN. Professor Ng was a member of the WHO Advisory Committee on Dengue and other Flavivirus Vaccines, and the advisor to the Novartis Institute of Tropical Diseases. She has collaborated with numerous BioTech/MedTech companies, including MP Biomedicals, Fujitsu Laboratories / Adaptamer Solutions, Austrianova Singapore etc., and is the inventor of 7 patents to date.

profile pic.png

Jennifer Lau

Chief Marketing Officer

  • LinkedIn Social Icon

Jennifer has more than 20 years of B2B/B2C working experience in pharmaceutical APIs, CDMO and biotech spaces for Asia Pacific markets, with strong track record in business development and strategic partnership with key customers & government authorities.  She had taken leadership and strategic positions in global multinational companies and start-up companies, and was the Vice President, Asia at Seqens Asia Pacific Limited.  She had managed numerous projects on M&A deals, due diligence, post-merger integration, greenfield project and digital transformation projects. Jennifer graduated with an MBA from the University of Hull in UK, and a BSc in Chemistry from Imperial College London.


Tiffany Lin

Chief Regulatory Officer

  • LinkedIn Social Icon

Prior to joining StratifiCare™, Tiffany was one of the main drivers of a Singapore-based cross-institutional effort to design and develop a cost-effective microfluidic diagnostic platform using gold nanoparticles for infectious disease testing. Tiffany is a certified Lead Auditor for ISO 13485 by the British Standards Institute, and spearheads the quality management system at StratifiCare™, to ensure safety and quality are built into each product.

Board of Advisors

leesa website-01.png

Leesa Soulodre

  • LinkedIn Social Icon

Leesa is a serial entrepreneur with over 20 years of experience in cutting edge of innovation, technology and strategy consulting. To date, Leesa has advised more than 400 multinationals and start-ups in 19 sectors across Europe, Asia-Pacific and the Americas, and led companies from Seed to $14B USD into new markets. Her work in strategy, reputation, risk, and technology has enabled companies with proven strategies, tools and technologies to acquire, protect and support their licenses to operate, mitigate risks and exploit opportunities for accelerated market access and revenue growth. Leesa holds expert industry expertise in deep technology, insurance, fintech, healthcare and pharmaceutical sectors.

Ted website-01.png

Edward (Ted) Ruppel

  • LinkedIn Social Icon

Ted Ruppel, President and CEO of Shape Memory Medical Inc., brings more than 25 years of entrepreneurial and medical device company management experience, including the IPO of Micrus Endovascular Corp. Ted was formerly EVP/CFO of Vascular Dynamics and Senior VP of R&D and Operations at Micrus Endovascular Corporation (acquired by J&J). He held previous management/operations roles at CBYON Inc., Biometric Imaging (acquired by BD), Applied Biosystems, and Spectra-Physics. Ted has a BSME from the University of Rochester and MBA (TRIUM - Jointly conferred by London School of Economics and Political Science, NYU Stern School of Business, and HEC Paris).


Ignatius Rasiah

  • LinkedIn Social Icon

Professor Ignatius Rasiah has over 25 years of experience in R&D management of product development in the industry and has held numerous key advisory and membership positions at national agencies, such as the National Lung Cancer Taskforce in Malaysia and the SG Tech Panel at Enterprise Singapore.


Prof. Rasiah is currently the Program Director at the Institute for Engineering Leadership, National University of Singapore. He was also the CTO at Perkin Elmer Optoelectronics and the VP for Breakthrough Research at Medtronic where his work focused on breakthrough technologies and business models relating to the surgical and patient monitoring spaces.

bottom of page